Uxbridge Middlesex, United Kingdom

Paul Bryan Wren


 

Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Paul Bryan Wren: Innovator in CXCR2 Inhibitors

Introduction

Paul Bryan Wren is an accomplished inventor based in Uxbridge, Middlesex, Great Britain. With two notable patents to his name, Wren has made significant contributions to the field of pharmacology, particularly in the development of CXCR2 inhibitors. His innovative approach to drug development showcases the pivotal role of inventors in advancing healthcare solutions.

Latest Patents

Wren's latest patents focus on 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors. The invention relates to 1-(3-sulfonylphenyl)-3-(cyclopent-2-en-1-yl)urea derivatives, which are utilized in treating or preventing diseases and conditions mediated by the CXCR2 receptor. Furthermore, these patents address compositions containing these derivatives and detail the processes for their preparation, reflecting Wren's commitment to enhancing therapeutic options.

Career Highlights

Wren is affiliated with GlaxoSmithKline Intellectual Property Development Limited, where he continues to innovate and develop groundbreaking treatments. His work is essential in addressing various health challenges through targeted therapies that impact the CXCR2 receptor, demonstrating the importance of novel pharmaceutical inventions in modern medicine.

Collaborations

During his career, Wren has collaborated with esteemed colleagues, including Weichun Chen and Ebere F. Igboko. These partnerships highlight the collaborative nature of research and development in the pharmaceutical industry, where diverse expertise contributes to the successful advancement of innovative solutions.

Conclusion

Paul Bryan Wren stands out as a significant figure in the field of pharmacology, with his innovative patents paving the way for potential advancements in medical treatments. His contributions to the development of CXCR2 inhibitors reflect the critical role of inventors in enhancing healthcare and improving patient outcomes. Wren's work at GlaxoSmithKline continues to inspire future innovations in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…